How does TYRA's PB Ratio compare to its peers?

TYRA is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (9.4x).

How does TYRA's PB Ratio compare vs other companies in the US Biotechs Industry?

TYRA is expensive based on its Price-To-Book Ratio (2.3x) compared to the US Biotechs industry average (1.9x).

What is TYRA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate TYRA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of TYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TYRA ($15.72) is trading below our estimate of [[fair value]] ($27.49)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Tyra Biosciences (Nasdaq:TYRA) - Stock Price, News & Analysis

TYRA Stock Overview

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. More details

TYRA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 42.8% below our estimate of its fair value

Analysts in good agreement that stock price will rise by 97.2%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 4.5% per year for the next 3 years

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Tyra Biosciences, Inc. Competitors

Capricor Therapeutics

NasdaqCM:CAPR

US$855.7m

Intercept Pharmaceuticals

NasdaqGS:ICPT

US$794.7m

Avid Bioservices

NasdaqCM:CDMO

US$786.7m

Kura Oncology

NasdaqGS:KURA

US$852.3m

Price History & Performance

Summary of all time highs, changes and price drops for Tyra Biosciences
Historical stock prices
Current Share Price	US$15.72
52 Week High	US$29.60
52 Week Low	US$10.60
Beta	1.08
11 Month Change	-28.32%
3 Month Change	-26.30%
1 Year Change	39.24%
33 Year Change	-37.35%
5 Year Change	n/a
Change since IPO	-39.54%

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21

Recent updates

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Mar 31

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Dec 15

Shareholder Returns

	TYRA	US Biotechs	US Market
7D	-3.0%	4.0%	2.2%
1Y	39.2%	18.3%	32.6%

Return vs Industry: TYRA exceeded the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: TYRA exceeded the US Market which returned 32.6% over the past year.

Price Volatility

Is TYRA's price volatile compared to industry and market?
TYRA volatility
TYRA Average Weekly Movement	11.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: TYRA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TYRA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2018	49	Todd Harris	tyra.bio

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.

Tyra Biosciences, Inc. Fundamentals Summary

How do Tyra Biosciences's earnings and revenue compare to its market cap?
TYRA fundamental statistics
Market cap	US$855.47m
Earnings (TTM)	-US$83.74m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-9.9x

P/E Ratio

Is TYRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TYRA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$83.74m
Earnings	-US$83.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.58
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did TYRA perform over the long term?

See historical performance and comparison

TYRA Stock Overview

Rewards

Risk Analysis

Tyra Biosciences, Inc. Competitors

NasdaqCM:CAPR

US$855.7m

NasdaqGS:ICPT

US$794.7m

NasdaqCM:CDMO

US$786.7m

NasdaqGS:KURA

US$852.3m

Price History & Performance

Recent News & Updates

Chief Financial Officer recently bought US$152k worth of stock

Now 22% undervalued after recent price drop

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Recent updates

Chief Financial Officer recently bought US$152k worth of stock

Now 22% undervalued after recent price drop

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

New major risk - Revenue and earnings growth

Co-Founder notifies of intention to sell stock

Price target increased by 8.2% to US$28.50

Co-Founder notifies of intention to sell stock

Price target increased by 9.8% to US$27.67

Now 20% undervalued

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Now 21% overvalued after recent price rise

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Now 22% overvalued after recent price rise

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price target increased by 7.7% to US$25.20

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 3000E Value Index

Insufficient new directors

Now 29% overvalued

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$24.20

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. announced that it expects to receive $200 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC

New minor risk - Share price stability

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Price target decreased by 9.0% to US$22.20

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Price target increased by 8.4% to US$24.40

Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia

Co-Founder exercised options and sold US$286k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Co-Founder & COO exercised options and sold US$350k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.3% to US$19.25

Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

High number of new directors

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$20.00

Tyra Biosciences Announces Chief Financial Officer Changes

Tyra Biosciences, Inc. Announces Appointment of Ali Fawaz as General Counsel and Secretary

Tyra Biosciences GAAP EPS of -$0.36

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 2000 Growth Index

High number of new directors

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

High number of new directors

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences, Inc. has completed an IPO in the amount of $172.8 million.

Shareholder Returns

Price Volatility